Latest: FDA Approves New Biosimilar for Oncology Treatment

PathAI and Moffitt Cancer Center Partner to Deploy AI Digital Pathology Platform, AISight® Dx

0 Mins
What You Should Know: – PathAI, a provider of AI and digital pathology solutions, and Moffitt Cancer Center, a top cancer hospital, have announced a multi-year strategic collaboration to deploy PathAI’s digital pathology platform, AISight® Dx, across Moffitt’s pathology programs. The partnership aims to transform cancer detection and research through the use of AI. AISight® ... Read More
Tags:
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago